Treatment of COVID-19 pneumonia with low-dose radiotherapy plus standard of care versus standard of care alone in frail patients
Open Access
- 31 March 2023
- journal article
- research article
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 199 (9) , 847-856
Abstract
Purpose To assess the efficacy of lung low-dose radiotherapy (LD-RT) in the treatment of patients with COVID-19 pneumonia. Materials and methods Ambispective study with two cohorts to compare treatment with standard of care (SoC) plus a single dose of 0.5 Gy to the whole thorax (experimental prospective cohort) with SoC alone (control retrospective cohort) for patients with COVID-19 pneumonia not candidates for admission to the intensive care unit (ICU) for mechanical ventilation. Results Fifty patients treated with LD-RT were compared with 50 matched controls. Mean age was 85 years in both groups. An increase in arterial oxygen partial pressure (PaO2)/fraction of inspired oxygen (PAFI) in the experimental LD-RT-treated group compared to the control group could not be found at 48 h after LD-RT, which was the primary endpoint of the study. However, PAFI values significantly improved after 1 month (473 vs. 302 mm Hg; p < 0.0001). Pulse oxymetric saturation/fraction of inspired oxygen (SAFI) values were also significantly higher in LD-RT-treated patients than in control patients at 1 week (405 vs. 334 mm Hg; p = 0.0157) and 1 month after LD-RT (462 vs. 326 mm Hg; p < 0.0001). All other timepoint measurements of the respiratory parameters were similar across groups. Patients in the experimental group were discharged from the hospital significantly earlier (23 vs. 31 days; p = 0.047). Fifteen and 26 patients died due to COVID-19 pneumonia in the experimental and control cohorts, respectively (30% vs. 48%; p = 0.1). LD-RT was associated with a decreased odds ratio (OR) for 1‑month COVID-19 mortality (OR = 0.302 [0.106–0.859]; p = 0.025) when adjusted for potentially confounding factors. Overall survival was significantly prolonged in the LD-RT group compared to the control group (log-rank p = 0.027). No adverse events related to radiation treatment were observed. Conclusion Treatment of frail patients with COVID-19 pneumonia with SoC plus single-dose LD-RT of 0.5 Gy improved respiratory parameters, reduced the period of hospitalization, decreased the rate of 1‑month mortality, and prolonged actuarial overall survival compared to SoC alone.Keywords
Funding Information
- SEOR
This publication has 23 references indexed in Scilit:
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Low‐dose whole‐lung radiation for COVID‐19 pneumonia: Planned day 7 interim analysis of a registered clinical trialCancer, 2020
- COVID-19: immunopathology and its implications for therapyNature Reviews Immunology, 2020
- Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic targetIntensive Care Medicine, 2020
- Low-Dose radiation therapy for benign pathologiesReports of Practical Oncology and Radiotherapy, 2020
- Coronavirus infection, ER stress, apoptosis and innate immunityFrontiers in Microbiology, 2014
- How radiotherapy was historically used to treat pneumonia: could it be useful today?2013
- Anti-inflammatory effects of low-dose radiotherapyStrahlentherapie und Onkologie, 2012
- Immunomodulatory Properties and Molecular Effects in Inflammatory Diseases of Low-Dose X-IrradiationFrontiers in Oncology, 2012
- Time course of anti-inflammatory effect of low-dose radiotherapy: Correlation with TGF-β1 expressionRadiotherapy and Oncology, 2008